{"nctId":"NCT01290874","briefTitle":"Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)","startDateStruct":{"date":"2011-03-30"},"conditions":["Asthma"],"count":1070,"armGroups":[{"label":"Tiotropium","type":"EXPERIMENTAL","interventionNames":["Drug: Tiotropium"]},{"label":"Salmeterol or Formoterol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol","Drug: Formoterol"]}],"interventions":[{"name":"Tiotropium","otherNames":["Spiriva"]},{"name":"Salmeterol","otherNames":["Serevent"]},{"name":"Formoterol","otherNames":["Foradil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Black (self-identified, with at least one biological parent identified as Black)\n2. Male and female subjects, ages 18-75\n3. Ability to provide informed consent\n4. Clinical history consistent with asthma for \\> 1 year.\n5. Ability to perform pulmonary function tests\n6. FEV1 \\> 40% of predicted\n7. Receiving inhaled corticosteroids (ICS)/LABA combination therapy, or ICS moderate dose monotherapy and baseline ACQ\\>1.25\n8. Non-smoker for past year (total lifetime smoking history \\< 10 pack-years)\n\nExclusion Criteria:\n\n1. Use of greater than the equivalent of 1000 mcg inhaled fluticasone daily\n2. Chronic use of oral corticosteroids or Anti IgE for asthma\n3. Lung disease other than asthma or diagnosis of vocal cord dysfunction.\n4. Significant medical illness (other than asthma) that is not stable.\n5. Pregnancy or lactation or an unwillingness to maintain effective birth control.\n6. History of a significant exacerbation of asthma or respiratory tract infection in the prior 4 weeks\n7. History of life-threatening asthma requiring treatment with intubation and mechanical ventilation within 5 years.\n8. Hypo sensitization therapy other than an established maintenance regimen.\n9. Use of inhaled anticholinergic therapy (ipratropium, tiotropium) in prior month\n10. Known contraindication to inhaled tiotropium e.g. narrow angle glaucoma, history of bladder neck obstruction or significant symptoms related to prostatic hypertrophy.\n11. Inability to speak and read English.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Asthma Exacerbation (Mean Number of Exacerbations/Person-year)","description":"We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in FEV1","description":"Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.018","spread":null},{"groupId":"OG001","value":"0.003","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Asthma Control Questionnaire (ACQ)","description":"Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).\n\nThe ACQ has six questions regarding symptoms, rescue short-acting Î²-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":null},{"groupId":"OG001","value":"-0.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Asthma Quality of Life (AQLQ)","description":"Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).\n\nThe AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Asthma Symptom Utility Index (ASUI)","description":"Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).\n\nThe ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.\n\n4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Symptom-Free Day Questionnaire (SFDQ)","description":"Average Change in Symptom-Free Days Per Participant Over 12 Months Using the Symptom-Free Day Questionnaire (SFDQ).\n\nThe asthma symptom free day questionnaire (SFDQ) quantifies the number of days with neither daytime nor nighttime asthma symptoms, nor awakenings due to asthma symptoms.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Rescue Medication Use","description":"Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.92","spread":null},{"groupId":"OG001","value":"-0.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Moderate Asthma Deterioration","description":"Average Change in Moderate Asthma Deterioration Per Participant Over 12 Months. The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":84,"n":532},"commonTop":["Disease Progression","Asthma"]}}}